Faculty

Institution

Unit

Venue

Jeremy Paul Cetnar

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Department Of Medicine

Department Of Otolaryngology - Head And Neck Surgery

Department Of Pediatrics

Division Of Oncological Sciences

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department Of Otolaryngology - Head And Neck Surgery

Center Of Molecular Biology Of Head And Neck Cancer

Molecular Biology of Head and Neck Cancer

Department of Medicine

Division Of Hematology/Medical Oncology

Division of Hematology & Medical Oncology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Department Of Medicine

Hematology and Medical Oncology

Department Of Pediatrics

Hematology and Oncology

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

OHSU Knight Cancer Institute

Oregon Health & Science University

NoneJeremy Paul Cetnar is currently serving as a Biostatistics Shared Resources faculty at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Jeremy Paul Cetnar

Oregon Health & Science University

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Evaluating Tissue-Agnostic Approvals in Thoracic and Head and Neck Malignancies. Cancers (2026)

tissue-agnostic approvalscancer detectiondiagnosisthoracic surgeryneck pathologyneck oncologycancer imagingoncologysurgerysurgical oncologyradiologythoracic oncology

Monitoring of Plasma and Urine Tumor-Derived Dna to Inform Bladder-Sparing Approaches for Patients With Muscle-Invasive Bladder Cancer. Proceedings of the National Academy of Sciences (2026)

genitourinary cancersbladder cancermolecular diagnosticscancer detectiononcologyurologydna analysis

Phase 2 Trial of Ozuriftamab Vedotin (Oz-V), a Conditionally Binding Ror2-Targeting Adc, in Patients With Treatment Refractory Hpv+ Opscc. Radiotherapy and Oncology (2026)

phase 2antiviral therapyimmunologymedicineozuriftamab vedotinpharmacologytherapeutic efficacyror2-targeting adcclinical trialstherapeutic targetsmedical virologyantiviral researchantiviral drugsclinical research

Successful Tarlatamab Rechallenge After Recurrent High-Grade Cytokine Release Syndrome in Chromothripsis-Mediated Sclc: A Case Report. JTO Clinical and Research Reports (2026)

recurrent high-grade crstranslational medicinehematologypathologymedicinepharmacologyclinical research

Swog S2414 (Insight): A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants With Early-Stage Non-Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting.. Journal of Clinical Oncology (2026)

immunologymedicinelung cancercellular therapycancer treatmentexperimental medicineclinical trialsimmunotherapyimmune checkpoint inhibitorsthoracic oncology

Landscape Assessment of Patient-Reported Outcome Item Coverage of Tyrosine Kinase Inhibitor–Associated Adverse Events. JNCI Journal of the National Cancer Institute (2025)

symptom managementinternal medicineoutcomes researchadverse drug reactionsadverse eventsapplied pharmacologylandscape assessmentdrug safetyclinical epidemiologymedicineoncologypharmacotherapyhealth sciencescancer careclinical effectiveness

Phase 2 Trial of Ozuriftamab Vedotin (Ba3021), a Conditionally Binding Ror2-Adc, in Patients With Heavily Pretreated Squamous Cell Carcinoma of the Head and Neck.. Journal of Clinical Oncology (2025)

phase 2ozuriftamab vedotinpathologypharmacologyoncogenescancer treatmentneck oncologyoncologycancer researchpharmacotherapysquamous cell carcinomaradiation oncology

Radiologists’ Perceptions of the 21St Century Cures Act. Journal of the American College of Radiology (2025)

internal medicinehealth policydiagnosismedicinemedical ethicspublic health ethicshealth caremedicalization

Supe_R Surveillance? Pet/Ct in Post-Treatment Nsclc and the Imperative of Proof Before Practice. Journal of Thoracic Oncology (2025)

internal medicineclinical investigationcompanion animalsevidence-based medicineproof before practicepost-treatment nsclcdiagnosismedicinenuclear medicineclinical guidancesupe_r surveillanceradiologyclinical research

Time Toxicity in Previously Untreated Metastatic or Unresectable Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: A Clinical Practice Review. Translational Lung Cancer Research (2025)

bronchial neoplasmlung cancerpathologyoncogenescancer treatmentoncologymetastasistime toxicityclinical practice reviewthoracic oncologyradiation oncology

1
2
3
4
5
8
10 / page

Jeremy Paul Cetnar

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Department Of Medicine

Department Of Otolaryngology - Head And Neck Surgery

Department Of Pediatrics

Division Of Oncological Sciences

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department Of Otolaryngology - Head And Neck Surgery

Center Of Molecular Biology Of Head And Neck Cancer

Molecular Biology of Head and Neck Cancer

Department of Medicine

Division Of Hematology/Medical Oncology

Division of Hematology & Medical Oncology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Department Of Medicine

Hematology and Medical Oncology

Department Of Pediatrics

Hematology and Oncology

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

OHSU Knight Cancer Institute

Oregon Health & Science University

NoneJeremy Paul Cetnar is currently serving as a Biostatistics Shared Resources faculty at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Jeremy Paul Cetnar

Oregon Health & Science University

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Evaluating Tissue-Agnostic Approvals in Thoracic and Head and Neck Malignancies. Cancers (2026)

tissue-agnostic approvalscancer detectiondiagnosisthoracic surgeryneck pathologyneck oncologycancer imagingoncologysurgerysurgical oncologyradiologythoracic oncology

Monitoring of Plasma and Urine Tumor-Derived Dna to Inform Bladder-Sparing Approaches for Patients With Muscle-Invasive Bladder Cancer. Proceedings of the National Academy of Sciences (2026)

genitourinary cancersbladder cancermolecular diagnosticscancer detectiononcologyurologydna analysis

Phase 2 Trial of Ozuriftamab Vedotin (Oz-V), a Conditionally Binding Ror2-Targeting Adc, in Patients With Treatment Refractory Hpv+ Opscc. Radiotherapy and Oncology (2026)

Successful Tarlatamab Rechallenge After Recurrent High-Grade Cytokine Release Syndrome in Chromothripsis-Mediated Sclc: A Case Report. JTO Clinical and Research Reports (2026)

recurrent high-grade crstranslational medicinehematologypathologymedicinepharmacologyclinical research

immunologymedicinelung cancercellular therapycancer treatmentexperimental medicineclinical trialsimmunotherapyimmune checkpoint inhibitorsthoracic oncology

Landscape Assessment of Patient-Reported Outcome Item Coverage of Tyrosine Kinase Inhibitor–Associated Adverse Events. JNCI Journal of the National Cancer Institute (2025)

phase 2ozuriftamab vedotinpathologypharmacologyoncogenescancer treatmentneck oncologyoncologycancer researchpharmacotherapysquamous cell carcinomaradiation oncology

Radiologists’ Perceptions of the 21St Century Cures Act. Journal of the American College of Radiology (2025)

internal medicinehealth policydiagnosismedicinemedical ethicspublic health ethicshealth caremedicalization

Supe_R Surveillance? Pet/Ct in Post-Treatment Nsclc and the Imperative of Proof Before Practice. Journal of Thoracic Oncology (2025)

bronchial neoplasmlung cancerpathologyoncogenescancer treatmentoncologymetastasistime toxicityclinical practice reviewthoracic oncologyradiation oncology

1
2
3
4
5
8
10 / page